NASDAQ:LENS - Presbia Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.52 -0.01 (-1.89 %) (As of 02/22/2019 04:00 PM ET)Previous Close$0.53Today's Range$0.4750 - $0.535052-Week Range$0.28 - $5.50Volume11,835 shsAverage Volume15,581 shsMarket Capitalization$8.92 millionP/E RatioN/ADividend YieldN/ABeta2.41 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland. Receive LENS News and Ratings via Email Sign-up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LENS Previous Symbol CUSIPN/A CIK1591096 Webwww.presbia.com Phone353-551-1487Debt Debt-to-Equity RatioN/A Current Ratio1.10 Quick Ratio1.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales892.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book2.89Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-16,990,000.00 Net MarginsN/A Return on Equity-396.87% Return on Assets-211.38%Miscellaneous Employees24 Outstanding Shares17,160,000Market Cap$8.92 million Next Earnings Date2/26/2019 (Estimated) OptionableNot Optionable Presbia (NASDAQ:LENS) Frequently Asked Questions What is Presbia's stock symbol? Presbia trades on the NASDAQ under the ticker symbol "LENS." How were Presbia's earnings last quarter? Presbia PLC (NASDAQ:LENS) announced its earnings results on Friday, August, 12th. The medical instruments supplier reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.07. The medical instruments supplier earned $0.01 million during the quarter, compared to analysts' expectations of $0.04 million. View Presbia's Earnings History. When is Presbia's next earnings date? Presbia is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Presbia. What price target have analysts set for LENS? 1 brokers have issued 12-month price targets for Presbia's shares. Their predictions range from $6.00 to $6.00. On average, they anticipate Presbia's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,053.8% from the stock's current price. View Analyst Price Targets for Presbia. What is the consensus analysts' recommendation for Presbia? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Presbia in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Presbia. What are Wall Street analysts saying about Presbia stock? Here are some recent quotes from research analysts about Presbia stock: 1. According to Zacks Investment Research, "Presbia PLC offers ophthalmic device. It is focused on the development and marketing of an optical lens implant for the treatment of presbyopia. The company's product consists of Presbia Flexivue Microlens(TM). Presbia PLC is based in Irvine, California. " (9/27/2018) 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a discounted cash flow-based net present value (NPV) approach to value Presbia. This yields a total value of $160M for the Flexivue Microlens product, using a 20% discount rate, 50% manufacturing and marketing offset, and a 12.5% tax rate as Presbia is domiciled in Ireland." (8/27/2018) Has Presbia been receiving favorable news coverage? News stories about LENS stock have trended somewhat positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Presbia earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the medical instruments supplier a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. Who are some of Presbia's key competitors? Some companies that are related to Presbia include Restoration Robotics (HAIR), PAVmed (PAVM), Interpace Diagnostics Group (IDXG), SANUWAVE Health (SNWV), Lianluo Smart (LLIT), DarioHealth (DRIO), Neovasc (NVCN), Dynatronics (DYNT), Hancock Jaffe Laboratories (HJLI), Biostage (BSTG), Invivo Therapeutics (NVIV), Alliqua Biomedical (ALQA), Avinger (AVGR), Valeritas (VLRX) and United American Healthcare (UAHC). What other stocks do shareholders of Presbia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Presbia investors own include Second Sight Medical Products (EYES), Athersys (ATHX), Actinium Pharmaceuticals (ATNM), Gran Tierra Energy (GTE), Allena Pharmaceuticals (ALNA), ArQule (ARQL), Nuvectra (NVTR), Ritter Pharmaceuticals (RTTR), Eyegate Pharmaceuticals (EYEG) and AEterna Zentaris (AEZS). Who are Presbia's key executives? Presbia's management team includes the folowing people: Mr. Vladimir Feingold, Consultant (Age 70)Mr. Mark T. Yung, CEO & Chairman (Age 45)Mr. Valeriano Lima, Corp. Controller, Head of Financial Planning and Analysis & Company Sec. (Age 37)Ms. Casey Jean Lind, Chief Operating Officer (Age 57)Ms. Marie Cha, Director of Direct Response Marketing When did Presbia IPO? (LENS) raised $50 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,200,000 shares at a price of $11.00-$13.00 per share. Jefferies served as the underwriter for the IPO. How do I buy shares of Presbia? Shares of LENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Presbia's stock price today? One share of LENS stock can currently be purchased for approximately $0.52. How big of a company is Presbia? Presbia has a market capitalization of $8.92 million and generates $10,000.00 in revenue each year. Presbia employs 24 workers across the globe. What is Presbia's official website? The official website for Presbia is http://www.presbia.com. How can I contact Presbia? Presbia's mailing address is SANDYFORD OFFICE CENTRE SUITE 7 17 CORRIG ROAD, DUBLIN 18 L2, . The medical instruments supplier can be reached via phone at 353-551-1487. MarketBeat Community Rating for Presbia (NASDAQ LENS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 140 (Vote Outperform)Underperform Votes: 128 (Vote Underperform)Total Votes: 268MarketBeat's community ratings are surveys of what our community members think about Presbia and other stocks. Vote "Outperform" if you believe LENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LENS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: What are the benefits of momentum investing?